Prognostic value of metastatic lymph node ratio and its effect on disease-free survival in colon cancer

Basit Öğe Kaydı
dc.contributor.authorAslan, O
dc.contributor.authorTopçu, R
dc.contributor.authorSezikli, I
dc.contributor.authorYüksek, MA
dc.contributor.authorPerçem, AK
dc.contributor.authorUğur, F
dc.date.accessioned2026-03-31T13:21:12Z
dc.date.available2026-03-31T13:21:12Z
dc.date.issued2025
dc.description.abstractIntroduction The metastatic lymph node ratio (MLNR) has been proposed as a meaningful prognostic indicator in colon cancer (CC). This study aimed to assess the prognostic relevance of MLNR by investigating its association with disease-free survival (DFS), overall survival (OS), and recurrence, and to compare its predictive value with traditional parameters, including the TNM classification and total lymph node count (TNLC). Materials and methods This retrospective, single-center study included patients who underwent surgical resection for colon cancer. Survival outcomes were analyzed using Kaplan-Meier survival curves and multivariate logistic regression. MLNR was evaluated in relation to demographic and clinical factors, including age, tumor location, surgical type, and the administration of adjuvant chemotherapy. The optimal MLNR cut-off value for predicting recurrence was determined via receiver operating characteristic (ROC) curve analysis. Results A total of 122 patients were analyzed. MLNR >0.125 was significantly associated with increased recurrence risk (adjusted HR: 7.0, p<0.001) and reduced DFS. Patients with an MLNR <= 0.125 demonstrated significantly longer DFS (p<0.001). MLNR emerged as an independent prognostic factor, offering potential prognostic benefit compared to TNLC in predicting both DFS and OS. Additionally, adjuvant chemotherapy was independently associated with a lower recurrence risk (Exp(B):0.234, p=0.038). Emergency surgery was found to be significantly correlated with poorer survival outcomes (p=0.023). Conclusion MLNR contributes additional prognostic information to the TNM staging system and may support more individualized risk stratification and decision-making regarding adjuvant therapy in colon cancer. Further large-scale prospective studies are warranted to validate these findings and to establish a clinically applicable MLNR threshold.
dc.identifier.doi10.3389/fonc.2025.1624798
dc.identifier.issn2234-943X
dc.identifier.pmid40936704
dc.identifier.urihttp://dx.doi.org/10.3389/fonc.2025.1624798
dc.identifier.urihttps://hdl.handle.net/11491/9594
dc.identifier.volume15
dc.identifier.wosWOS:001568773900001
dc.language.isoen
dc.publisherFRONTIERS MEDIA SA
dc.relation.ispartofFRONT ONCOL
dc.subjectcolon cancer
dc.subjectmetastatic lymph node ratio
dc.subjectprognosis
dc.subjectsurvival
dc.subjectdisease recurrence
dc.subjectadjuvant chemotherapy
dc.titlePrognostic value of metastatic lymph node ratio and its effect on disease-free survival in colon cancer
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu